:: Volume 30, Issue 6 (2-2023) ::
Journal of Ilam University of Medical Sciences 2023, 30(6): 32-44 Back to browse issues page
The Preventive Effect of Topical Administration of Human Mesenchymal Stem Cells-Conditioned Medium (MSC-CM) on DNCB-Induced Atopic Dermatitis-Like Model in Mice
Zahra Mohammadi1 , Majid Hassanpour-ezatti * 2
1- Dept of Biology, School of Basic Sciences, Shahed University, Tehran, Iran
2- Dept of Biology, School of Basic Sciences, Shahed University, Tehran, Iran , hassanpour@shahed.ac.ir
Abstract:   (778 Views)
Introduction: Atopic dermatitis (AD) is a chronic inflammatory skin disease for which there is no adequate treatment. Mesenchymal stem cells have already been used to treat inflammatory diseases.  The present study investigated the effect of the administration of human mesenchymal stem cells-conditioned medium (MSC-CM) on the AD model and its relationship with central pain, the level of oxidative, and inflammatory stress factors in the skin.
Material & Methods: The AD model was established by topical administration of a 2% 4,2-dinitrochlorobenzene (DNCB) solution on the dorsal and ear skin of mice. Mice received topical MSC-CM and betamethasone ointment as a positive control three times a day for 2 weeks. Skin interleukin-4 (IL-4) and malondialdehyde (MDA) levels were measured by the ELISA method in all groups. Changes in nociception were assessed by the tail flick test. Histological changes in the body and ear skins were evaluated after hematoxylin-eosin (H&E) staining, and mast cells number in toluidine blue-stained sections were counted in this study.
(Ethic code: IR.SHAHED.REC.1399.095)
Findings: Topical administration of MSC-CM and betamethasone was able to reduce pain, inflammation, and changes of dermis thickness in the dorsal and ear skins, as well as the infiltration of mast cells in the skin of groups treated with DNCB. Moreover, MSC-CM, similar to betamethasone, decreased the level of IL-4 and MDA levels in the skin of DNCB receiving groups.
Discussion & Conclusion: The increase in IL-4 levels and lipid peroxidation play an important role in inducing AD-like lesions in the skin of the mouse in the DNCB model; in addition, the topical application of the MSC-CM is a potential therapeutic agent for AD.
 
Keywords: Atopic dermatitis, Conditioned culture media, Dinitrochlorobenzene, Interleukin-4, Mesenchymal Stem Cells
Full-Text [PDF 1997 kb]   (273 Downloads)    
Type of Study: Research | Subject: animal physiology
Received: 2022/05/28 | Accepted: 2022/09/10 | Published: 2023/02/4
References
1. Ständer S, Simpson EL, Guttman-Yassky E, Thyssen JP, Kabashima K, Ball SG, et al. Clinical Relevance of Skin Pain in Atopic Dermatitis. J Drugs Dermatol 2020; 19:921-6. doi: 10.36849/JDD.2020.5498.
2. Na CH, Chung J, Simpson EL. Quality of Life and Disease Impact of Atopic Dermatitis and Psoriasis on Children and Their Families. Children (Basel) 2019; 6:133. doi: 10.3390/children6120133.
3. Mulick AR, Allen V, Williams HC, Grindlay DJC, Pearce N, Abuabara K, et al. Classifying atopic dermatitis: protocol for a systematic review of subtypes (phenotypes) and associated characteristics. BMJ Open 2018; 8: e023097. doi: 10.1136/bmjopen-2018-023097.
4. Yalcin AD. An overview of the effects of anti-IgE therapies. Med Sci Monit 2014; 20:1691-9. doi: 10.12659/MSM.890137.
5. Brown SJ, McLean WH. Eczema genetics: current state of knowledge and future goals. J Invest Dermatol 2009; 129:543-52. doi: 10.1038/jid.2008.413.
6. Bajgai J, Fadriquela A, Ara J, Begum R, Ahmed MF, Kim CS, et al. Balneotherapeutic effects of high mineral spring water on the atopic dermatitis-like inflammation in hairless mice via immunomodulation and redox balance. BMC Complement Altern Med 2017;17:481. doi: 10.1186/s12906-017-1985-8.
7. da Costa Gonçalves F, Grings M, Nunes NS, Pinto FO, Garcez TN, Visioli F, et al. Antioxidant properties of mesenchymal stem cells against oxidative stress in a murine model of colitis. Biotechnol Lett 2017; 39:613-22. doi: 10.1007/s10529-016-2272-3.
8. Li K, Yan G, Huang H, Zheng M, Ma K, Cui X, et al. Anti-inflammatory and immunomodulatory effects of the extracellular vesicles derived from human umbilical cord mesenchymal stem cells on osteoarthritis via M2 macrophages. J Nanobio-technology 2022; 20:38. doi: 10.1186/s12951-021-01236-1.
9. Kay AG, Long G, Tyler G, Stefan A, Broadfoot SJ, Piccinini AM, et al. Mesenchymal Stem Cell-Conditioned Medium Reduces Disease Severity and Immune Responses in Inflammatory Arthritis. Sci Rep 2017; 7:18019. doi: 10.1038/s41598-017-18144-w.
10. Zhang EY, Chen AY, Zhu BT. Mechanism of dinitrochlorobenzene-induced dermatitis in mice: role of specific antibodies in pathogenesis. PLoS One 2009;4: e7703. doi: 10.1371/journal.pone.0007703.
11. Duo L, Hu L, Tian N, Cheng G, Wang H, Lin Z, et al. TRPV1 gain-of-function mutation impairs pain and itch sensations in mice. Mol Pain 2018; 14:1744806918762031. doi: 10.1177/1744806918762031.
12. Jang HY, Koo JH, Lee SM, Park BH. Atopic dermatitis-like skin lesions are suppressed in fat-1 transgenic mice through the inhibition of inflammasomes. Exp Mol Med 2018; 50:1-9. doi: 10.1038/s12276-018-0104-3.
13. Filip A, Daicoviciu D, Clichici S, Bolfa P, Catoi C, Baldea I, et al. The effects of grape seeds polyphenols on SKH-1 mice skin irradiated with multiple doses of UV-B. J Photochem Photobiol B 2011; 105:133-42. doi: 10.1016/j.jphotobiol.2011.08.002.
14. Conti M, Morand PC, Levillain P, Lemonnier A. Improved fluorometric determination of malonal-dehyde. Clin Chem 1991; 37:1273-5.
15. McLeod JJ, Baker B, Ryan JJ. Mast cell production and response to IL-4 and IL-13. Cytokine 2015; 75:57-61. doi: 10.1016/j.cyto.2015.05.019.
16. Han M, Wang X, Wang J, Lang D, Xia X, Jia Y, et al. Ameliorative effects of epigallocatechin-3-gallate nanoparticles on 2,4-dinitrochlorobenzene induced atopic dermatitis: A potential mechanism of inflammation-related necroptosis. Front Nutr 2022; 9:953646. doi: 10.3389/fnut.2022.953646.
17. Martin SF, Esser PR, Weber FC, Jakob T, Freudenberg MA, Schmidt M, et al. Mechanisms of chemical-induced innate immunity in allergic contact dermatitis. Allergy 2011; 66:1152-63. doi: 10.1111/j.1398-9995.2011.02652. x.
18. Chiricozzi A, Maurelli M, Peris K, Girolomoni G. Targeting IL-4 for the Treatment of Atopic Dermatitis. Immunotargets Ther 2020; 9:151-156. doi: 10.2147/ITT.S260370.
19. Xian D, Guo M, Xu J, Yang Y, Zhao Y, Zhong J. Current evidence to support the therapeutic potential of flavonoids in oxidative stress-related dermatoses. Redox Rep 2021; 26:134- 46. doi: 10.1080/13510002.2021.1962094.
20. Wang S, Qu X, Zhao RC. Clinical applications of mesenchymal stem cells. J Hematol Oncol 2012; 5:19. doi: 10.1186/1756-8722-5-19.
21. Takahashi H, Ohnishi S, Yamamoto Y, Hayashi T, Murao N, Osawa M, et al. Topical Application of Conditioned Medium from Hypoxically Cultured Amnion-Derived Mesenchymal Stem Cells Promotes Wound Healing in Diabetic Mice. Plast Reconstr Surg 2021; 147:1342-52. doi: 10.1097/PRS.0000000000007993.
22. Horn AP, Bernardi A, Luiz Frozza R, Grudzinski PB, Hoppe JB, de Souza LF, et al. Mesenchymal stem cell-conditioned medium triggers neuroin-flammation and reactive species generation in organotypic cultures of rat hippocampus. Stem Cells Dev 2011; 20:1171-81. doi: 10.1089/scd.2010.0157.
23. Bloom DD, Centanni JM, Bhatia N, Emler CA, Drier D, Leverson GE, et al. A reproducible immunopotency assay to measure mesenchymal stromal cell-mediated T-cell suppression. Cyto-therapy 2015; 17:140-51. doi: 10.1016/j.jcyt.2014.10.002.
24. Seetharaman R, Mahmood A, Kshatriya P, Patel D, Srivastava A. Mesenchymal Stem Cell Conditioned Media Ameliorate Psoriasis Vulgaris: A Case Study. Case Rep Dermatol Med 2019; 2019:8309103. doi: 10.1155/2019/8309103.
25. Trallori E, Ghelardini C, Di Cesare Mannelli L. Mesenchymal stem cells, implications for pain therapy. Neural Regen Res 2019; 14:1915-16. doi: 10.4103/1673-5374.259615.

Ethics code: IR.SHAHED.REC.1399.095



XML   Persian Abstract   Print



Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 30, Issue 6 (2-2023) Back to browse issues page